HC Wainwright Reaffirms “Buy” Rating for Dyne Therapeutics (NASDAQ:DYN)

HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Wednesday morning,Benzinga reports. They currently have a $55.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. Piper Sandler reiterated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Oppenheimer reissued an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Morgan Stanley raised their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Trading Down 6.1 %

DYN traded down $2.07 on Wednesday, reaching $32.06. The company had a trading volume of 250,371 shares, compared to its average volume of 1,489,884. The company has a market capitalization of $3.22 billion, a P/E ratio of -9.59 and a beta of 1.10. The company has a fifty day moving average of $32.64 and a 200-day moving average of $35.12. Dyne Therapeutics has a one year low of $9.76 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts predict that Dyne Therapeutics will post -2.99 EPS for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the transaction, the director now directly owns 234,127 shares in the company, valued at approximately $8,533,929.15. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares in the company, valued at approximately $8,533,929.15. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John Cox bought 32,000 shares of the stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. This represents a -100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 158,975 shares of company stock worth $5,693,789. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its stake in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the last quarter. Quantbot Technologies LP purchased a new position in Dyne Therapeutics in the third quarter valued at about $34,000. US Bancorp DE grew its stake in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. Values First Advisors Inc. acquired a new position in Dyne Therapeutics in the 3rd quarter worth about $62,000. Finally, KBC Group NV raised its stake in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.